MYRIAD GENETICS, INC. (NASDAQ:MYGN) Files An 8-K Regulation FD Disclosure
ITEM 7.01
Regulation FD Disclosure
On March 14, 2019, Myriad Genetics, Inc. (“Myriad” or the “Company”) issued a press release announcing that the Medicare Administrative Contractor Palmetto GBA MolDx has issued a final local coverage determination (LCD) for the myPath® Melanoma test.A copy of the press release announcing the LCD is furnished as Exhibit99.1 to this Current Report on Form 8-K and incorporated herein by reference.
Safe Harbor Statement
This communication, including the exhibits attached hereto, contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These “forward-looking statements” are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those described or implied in the forward-looking statements.
Page 2
|
ITEM 9.01 |
Financial Statements and Exhibits. |
(d)
|
Exhibit Number |
Description |
|
99.1 |
Press Release dated March 14, 2019. |
The exhibit(s) may contain hypertext links to information on our website or other parties’ websites. The information on our website and other parties’ websites is not incorporated by reference into this Current Report on Form 8-K and does not constitute a part of this Form 8-K.
In accordance with General Instruction B-2 of Form 8-K, the information set forth in Item 7.01 and in Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Page 3
MYRIAD GENETICS INC Exhibit
EX-99.1 2 mygn-ex991_6.htm EX-99.1 mygn-ex991_6.htm Exhibit 99.1 News Release Media Contact:Ron RogersInvestor Contact:Scott Gleason (801) 584-3065(801) 584-1143 [email protected]@myriad.com Myriad’s myPath® Melanoma Test Receives Medicare Coverage Test Will Help Patients Receive a Definitive Diagnosis for a Suspicious Skin Lesion Biopsy SALT LAKE CITY,…
To view the full exhibit click here
About MYRIAD GENETICS, INC. (NASDAQ:MYGN)
Myriad Genetics, Inc. is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services, such as finance, human resources, legal and information technology. Its molecular diagnostic tests include myRisk Hereditary Cancer, BRACAnalysis CDx and COLARIS.
